We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Gustave Roussy Cancer Center, Villejuif, France
Alexandra Leary, MD, PhD is the co-director of the Department of Medicine and a medical oncologist in gynecological oncology at Gustave Roussy in Paris, as well as president of the national GINECO (Groupe d’Investigateurs National pour l’Etude des Cancers de l’Ovaire et du Sein) trials group. read more
She has a special focus on early-phase drug development in ovarian, cervical and uterine cancers and is also team leader for the gynecological oncology translational research team within the laboratory of Predictive Biomarkers and Novel Targeted Therapeutics (INSERM U981) at Gustave Roussy.
Dr Leary trained in medical oncology at the Royal Marsden Hospital in London and obtained a PhD from the Institute of Cancer Research/University of London. Internationally, she is a member of the European Network for Gynaecological Oncological Trials (ENGOT) translational research group, sits on the Strategic Comittee of the Gynecological Cancer InterGroup (GCIG), co-chairs the GCIG phase II trial group, and serves on the European Society of Medical Oncology (ESMO) faculty. She was also the track chair for gynaecology at ESMO 2022 and ESMO Asia 2023.
Dr Alexandra Leary discloses: Advisory board or panel fees from AbbVie, AstraZeneca, Daiichi Sankyo, GSK, ImmunoGen, MSD, pharma& and Zentalis. Consultancy fees from Owkin and Pegascy. Grants/research support from AstraZeneca and Zentalis.
Gustave Roussy Cancer Center, Villejuif, France
Juan Francisco Grau, MD, is a medical oncologist specializing in gynaecologic cancers. read more
He trained at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology in Barcelona, Spain, gaining expertise in conducting and developing clinical trials under Dr Ana Oaknin. He later completed a Translational Research Fellowship at Gustave Roussy under Dr Alexandra Leary, focusing on immunoprofiling in gynaecological cancers. In 2025, he began a PhD at Paris-Saclay University – Gustave Roussy, studying the tumour microenvironment in mismatch repair-deficient endometrial cancer to refine immunotherapy resistance prediction and explore therapeutic strategies to reverse it.
Dr Juan Francisco Grau discloses: Advisory board or panel fees from AstraZeneca. Speaker Bureau fees from AstraZeneca, GSK and pharma&.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a
.Explore the latest in medical education and stay current in your field. Create a free account to track your learning.